← Back to Clinical Trials
Recruiting NCT07845656

NCT07845656 A Home-based Multicomponent Exercise Intervention Program Based on the Fogg Behavior Model (FBM) for Older Adults With Osteosarcopenia and Frailty

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07845656
Status Recruiting
Phase —
Sponsor Jiawei Jiang
Condition Osteosarcopenia; Frailty; Older Adults
Study Type INTERVENTIONAL
Enrollment 70 participants
Start Date 2026-01-01
Primary Completion 2026-12-31

Eligibility & Interventions

Sex All sexes
Min Age 60 Years
Max Age 85 Years
Study Type INTERVENTIONAL
Interventions
Multi-component home-based exercise intervention based on the Fogg Behavior Modelroutine health education and standard nursing care for osteoporosis and regular outpatient follow-up, without extra exercise and nutritional intervention.

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 70 participants in total. It began in 2026-01-01 with a primary completion date of 2026-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to construct and evaluate a home-based multicomponent exercise intervention program based on the Fogg Behavior Model for older adults with osteosarcopenia and frailty. Eligible participants will be randomly divided into two groups. The intervention group will receive the home multicomponent exercise guidance built on Fogg Behavior Model, while the control group will get routine health education. We will compare frailty status, muscle strength, physical function,bone mineral density and quality of life between the two groups at baseline, 3 months and 6 months, to explore whether this intervention can improve physical function and reduce frailty in elderly patients with osteosarcopenia.

Eligibility Criteria

Inclusion Criteria: 1. The disease is in stable condition. 2. Aged 60-85 years or older. 3. Meet the diagnostic criteria in the 2022 Expert Consensus on Sarcopenia-Osteoporosis. 4. The score of frailty scale is ≥1, indicating patients are in pre-frailty or frailty status. 5. Clear consciousness, normal communication, capable of cooperating with exercise intervention; not living alone and will not leave the residence within half a year. 6. Own a smartphone and voluntarily participate in this study. Exclusion Criteria: 1. Severe cardiopulmonary, hepatic or renal dysfunction. 2. Uncontrolled severe neurological or psychiatric diseases. 3. Recent fracture or unable to perform exercise training. 4. Malignant tumor, severe infectious disease. 5. Participate in other exercise intervention studies simultaneously. 6. Cognitive impairment and cannot cooperate with follow-up.

Contact & Investigator

Central Contact

Li Sun, Master' degree

✉ sunliborntowin@126.com

📞 8615896264283

Frequently Asked Questions

Who can join the NCT07845656 clinical trial?

This trial is open to participants of all sexes, aged 60 Years or older, up to 85 Years, studying Osteosarcopenia; Frailty; Older Adults. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07845656 currently recruiting?

Yes, NCT07845656 is actively recruiting participants. Contact the research team at sunliborntowin@126.com for enrollment information.

Where is the NCT07845656 trial being conducted?

This trial is being conducted at Nantong, China, Nantong, China.

Who is sponsoring the NCT07845656 clinical trial?

NCT07845656 is sponsored by Jiawei Jiang. The trial plans to enroll 70 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology